Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at EHA 2021

Shots:

The P-III MAIA study assessing Darzalex + lenalidomide & dexamethasone (DRd) vs Rd in 737 newly diagnosed patients aged 45-90yrs. with MM ineligible for high-dose CT & ASCT
MAIA longer-term follow-up analysis showed i.e @5yrs., OS rate (66% vs 53%), PFS rate (53% vs 29%), ORR (93% vs 82%) & median time to next treatment (not reached vs 42.4 mos.), no new safety concerns were identified
The prespecified interim analysis after a median follow-up of 56.2mos. showed a 32% reduction in risk of death, m-OS was not reached, mPFS (not reached vs 34.4mos.) PFS benefit with 47% reduction in risk of disease progression or death

Click here to read full press release/ article | Ref: PR Newswire | Image: Investing.com